Research benefits of storing genitourinary samples: 16SrRNA sequencing to evaluate vaginal bacterial communities by Wagner, J et al.
Letter to the Editor
Research benefits of storing genitourinary
samples: 16S rRNA sequencing to
evaluate vaginal bacterial communities
Dear Editor,
Using well-characterised, but old and carefully
frozen genital tract research samples may be a cost-
eﬀective way of performing metagenomic studies, but
risks loss of low abundance (but relevant) bacterial spe-
cies DNA. Moi et al.1 used 16S rRNA and UreDNA
sequencing to detect ureaplasmas in frozen urine sam-
ples collected from 362 men with NGU in 2010–2011.
They found that urethral inﬂammatory responses to
ureaplasmas were less severe than to Chlamydia tracho-
matis and Mycoplasma genitalium.
In a pilot study in 2015, we used 16S rRNA sequen-
cing to evaluate bacterial communities in 20 stored self-
taken vaginal samples collected in 2004–2008 for the
Prevention of Pelvic Infection (POPI) chlamydia
screening trial.2 The mean age of the women whose
samples were tested was 18 years (range: 16 to 26),
and three were positive for C. trachomatis (including
one co-infected with Neisseria gonorrhoeae) and one
for M. genitalium. Despite up to 11 years of storage
in Gen-Probe Aptima transport medium at 80C,
DNA integrity was adequate in all the 20 samples ana-
lysed including four postal samples.
The full-length bacterial 16S rRNA gene was ampli-
ﬁed using New England Biolab Q5 high-ﬁdelity poly-
merase kit. Equimolar library mix was prepared and
sequenced using PacBio SMRT sequencing technology.
Downstream bioinformatics analysis was performed
using Mothur (version 1.34.4).
We obtained 73,590 raw sequences from 22 samples,
including one negative and one positive control, of
which 41,166 were of high quality. Four samples with
low sequence number (<500 sequences) were excluded.
In the remaining 16 samples, 65 unique oligotype spe-
cies were identiﬁed, of which 14 had a minimum abun-
dance of 0.1% (Figure 1). Burkholderia species were
identiﬁed as contaminants and removed.
Five oligotype species had a minimum abundance
of 1%: Lactobacillus crispatus (52.8%), Lactobacillus
iners (33.7%), Gardnerella vaginalis (3.5%),
Lactobacillus gasseri (2.9%), and Finegoldia magna
(1.1%). Six samples were dominated by L. iners (red
bar), and seven samples by L. crispatus (blue bar).
Sample 581_lbc2, previously assessed as bacterial
vaginosis (BV) intermediate, was dominated by G.
vaginalis. Patient 1117, the one positive for C. tracho-
matis and N. gonorrhoeae, had the highest number of
Megasphaera elsdenii, which has been reported in BV.
Patient 586_Ibc6 described her ethnicity as black other
and had the largest bacterial diversity among all
patients analysed.
We note that C. trachomatis and N. gonorrhoeae
were not detected in the samples. This was not unex-
pected given that we sequenced from vulvo-vaginal
swabs, and the source of whole organism for these
pathogens in the female reproductive tract is the
cervix. Although nucleic acid ampliﬁcation tests
using speciﬁc primers for C. trachomatis and N. gonor-
rhoeae are highly accurate in vulvo-vaginal swabs, the
relative low abundance of their genomic DNA in these
samples would mean that the generic 16S rRNA pri-
mers were likely to preferentially bind to higher load
organisms.
Like Moi et al.,1 we found that carefully charac-
terised samples can be used after many years of storage
for the investigation of research questions using 16S
rRNA sequencing or PCR.3–5
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